Plicera
Navigation Links
Plicera in Medical Technology
Phase 2 Clinical Trials Initiated
CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus
Therapeutics, a biopharmaceutical company developing small
molecule, orally-administered pharmacological chaperones for the
treatment of a range of human genetic diseases, announced today
that it will present p...
...he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
...olly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay ti...Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
...trengthens our protection in the United States for plicera in Gaucher and is one example of our ongoing effor...armacological chaperone technology platform." plicera is currently being studied in an ongoing Phase 2 s...e third quarter of 2009. Amicus is developing plicera as part of a strategic collaboration with Shire Hu...Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. Forward-Looking Statements This press release contain......he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
... for the ongoing 6-month Phase 2 clinical trial of plicera in patients naive to ERT to include modified doses... The Company has modified its development plan for plicera to include a study of the pharmacokinetics of plicera in Gaucher patients. In addition, the company no l...Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
...Nashville, TN. The data demonstrate the ability of plicera to increase levels of the target enzyme in cells d...l data from both studies will also be presented. plicera is designed to selectively bind to and stabilize G... The following is a summary of the preclinical plicera data being presented at ACMG. - In vitro ex...Plicera in Biological Technology
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...rldwide will participate in this trial. plicera (TM) (afegostat tartrate) for the treatment of ...inical trial of the Company's investigational drug plicera is ongoing. This 6-month study is designed to eval..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...Publication of Shire plc's Annual Report 2008
...IGAL and AT2220, in markets outside the US. plicera (HGT-3410 for the treatment of Gaucher disease) plicera is an orally-administered, small molecule pharmaco...port the previously reported interim findings that plicera was generally safe and well tolerated at all doses...Amicus Therapeutics Announces Change to Board of Directors
... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
... be available in the first quarter of 2009. plicera (TM) (isofagomine tartrate) for the treatment o...on executing its ongoing Phase 2 clinical trial of plicera in Gaucher disease. This 6-month study is designed..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD -G ...Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
...medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...Amicus Therapeutics Announces Third Quarter 2008 Financial Results
...ucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of plicera in patients naive to ERT is ongoing and Amicus expects the results of this ...harmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration, valued at up to $440 million including a......s Phase 2 trial support the previously reported interim findings that plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to plicera in markets outside the US. HGT-3510 - Pompe disease - In June 2008 Ami...
Amicus Therapeutics Announces First Quarter 2008 Financial Results
...macological chaperone Plicera. Results showed that plicera was generally safe and well tolerated at all doses...protocol for the 6-month Phase 2 clinical trial of plicera patients naive to ERT to include modified doses an...compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration valued at up to ...Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
...ine) METAZYM(TM) (arylsulfatase-A) MEZAVANT(R) (mesalazine) PENTASA (mesalamine) (trademark of Ferring) plicera (isofagomine tartrate) (trademark of Amicus) RAZADYNE (galantamine) (trademark of Johnson & Johnson ...Other TagsDissectingSleepSleepSleepSleepComingComingComingStimulationStimulationSurprisePathwayPathwayPathwayChimpanzeeArcticArcticArcticDefenseDefenseDefenseOther Contentsnegativenegativenegativenegativenegativenegativenegativenegativenegativenegativechordchordimpulseimpulseimpulseimpulseimpulsenervesnervesnervesnervesnervesnervesnervesneurulaneutrophilsneutrophilsneutrophilsneutrophils
DissectingSleepComingStimulationExxonAirborneTyrannosaurSurprisePolynesiaPathwayChimpanzeeArcticBeekeepersDefense
(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... led by the Wellcome Trust Sanger Institute announce the ... cancers are caused by mutations in the DNA of ... The studies, of a malignant melanoma and a lung ... mutations in the genomes of two cancers. , Lung ... almost all are associated with smoking. The number of ...
(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
(Date:12/16/2009)... MassBio promote Massachusetts companies through annual marketing campaign , ... ... -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , ,Genetown is sponsored by MassBio and ... industries. The campaign places each entity’s brand on an ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Thriving Bioscience Region Leaves Its Mark 2(Date:12/16/2009)... 8, 2009 National Instruments (Nasdaq: ... measurement and control, and DENSO Robotics, a ... robotics technology, today announced their collaboration to ... DENSO robotic arms. The collaboration increases productivity ... flexible manufacturing applications. In today,s trend toward ...
(Date:12/16/2009)... Dec. 9 CSC (NYSE: ... American Association for Laboratory Accreditation awarded the ... 17025:2005 accreditation to the company,s Test Lab, ... Labs located in Fairmont, W.Va. The Test ... in the world to achieve this accomplishment. ...
(Date:12/15/2009)... The 2009 Frost & Sullivan European Border ... Sagem Securite (Safran Group) for its innovative ... the company,s expertise in advanced biometric technology ... value-added products to end users. ,, ... Securite has been involved in delivering identification ...
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4This idea doesnt stink 3A New tech cuts industrial odors pollutants 9701 1This idea doesnt stink 3A New tech cuts industrial odors pollutants 9701 2Solta Medical Launches New Fraxel re 3Astore 28R 29 Dual Laser System 55402 1Solta Medical Launches New Fraxel re 3Astore 28R 29 Dual Laser System 55402 2Solta Medical Launches New Fraxel re 3Astore 28R 29 Dual Laser System 55402 3Hill Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 55399 1Hill Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 55399 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |